Tag: active surveillance

I came across a journal article by a Brazilian urologic specialist, Dr. Stênio Cássio Zequi of the Camargo Cancer Center in São Paulo, Brazil. He asks if focal therapy will be the next step in prostate cancer management. Before expressing his opinion, he writes what amounts to a “snapshot” of the current state of prostate cancer treatment... keep reading

Has this ever happened to you? You don’t feel well or you have a weird symptom and you make an appointment with your doctor. After discussion and maybe a test or two, your doc gives you a diagnosis. You have a condition that is not life threatening at the moment (such as low-risk prostate cancer) keep reading

As promised, the analyzed results of the MEAL study (2011-15) described below were finally published by JAMA in January, 2020.iIf the authors were hoping to show that increasing vegetable intake could slow progression of prostate cancer (PCa) among patients on Active Surveillance, they must have been... keep reading

More and more prostate cancer patients and their doctors are turning to Active Surveillance (AS). Data shows that for carefully chosen low risk patients, AS is a way to hold off on treatment like surgery or radiation without significantly increasing the chances of death from prostate cancer... keep reading

Previously, we posted a recommended caution that men of African American descent discuss possible risks of going on Active Surveillance (AS) even when early clinical factors suggested they qualify for AS. Then, the authors of a 2018 paper noted that the observational studies encouraging more use of AS were largely composed of White men, raising the question of whether positive results of those studies should be applied to Black men. After reviewing studies that focused on Black men, they concluded... keep reading

For the right prostate cancer (PCa) patient, Active Surveillance (AS) is a good thing. Urologic professionals now see eye-to-eye on monitoring with a focus on “preventing overtreatment in patients for whom the benefit of treatment deferral outweighs the need for immediate oncologic control.”[i] That’s a technical way of saying, if you don’t have clinically significant keep reading

Why has it taken so long for someone to denounce the digital rectal exam (DRE) as a screening tool? Despite expert opinion against the DRE, many primary care doctors still do a DRE as part of routine annual checkups. The DRE has also been considered an essential monitoring practice for prostate cancer (PCa) patients on keep reading

If you’ve been diagnosed with low-risk prostate cancer, chances are your doctor has said you may be a candidate for Active Surveillance (AS). The National Cancer Institute defines AS as a cancer management strategy to avoid or delay treatments with side effect risks. It “involves closely watching a patient’s condition but not giving any treatment keep reading

Dr. Brawley holds an important position as the chief medical officer of the American Cancer Society. As a practicing oncologist, he is considered a world cancer expert, and he is the author of “How We Do Harm: A Doctor Breaks Ranks About Being Sick In America.” So when Dr. Brawley speaks out, he’s worth listening to... keep reading

Manly. Virile. Macho. Hunky. Stud. How does man come to merit such terms? It’s due to his male hormones. When produced by special glands or organs, they are released into the bloodstream in order to “instruct” the development and function of male features. They help create and regulate a man’s masculine attributes, the physical and keep reading